RAPP Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Rapport Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.95 |
| 52 Week High | US$29.74 |
| 52 Week Low | US$16.55 |
| Beta | 0 |
| 11 Month Change | -28.33% |
| 3 Month Change | 0.67% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| RAPP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -21.5% | -6.2% | -2.2% |
| 1Y | n/a | 9.8% | 30.1% |
Return vs Industry: Insufficient data to determine how RAPP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RAPP performed against the US Market.
Price Volatility
| RAPP volatility | |
|---|---|
| RAPP Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RAPP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RAPP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 58 | Abe Ceesay | www.rapportrx.com |
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders.
Rapport Therapeutics, Inc. Fundamentals Summary
| RAPP fundamental statistics | |
|---|---|
| Market cap | US$803.95m |
| Earnings (TTM) | -US$71.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.7x
P/E RatioIs RAPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAPP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$71.85m |
| Earnings | -US$71.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RAPP perform over the long term?
See historical performance and comparison